Wells Fargo’s NewAmsterdam Pharma NAMS Stock Holding History

Wells Fargo’s Portfolio NAMS Stock Details NAMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$129K	Buy	+3,800	New	+$125K	﹤0.01%	5429

Other funds holding NAMS

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

Wells Fargo's NAMS Position: Q2 2026 in Review

Wells Fargo increased its NewAmsterdam Pharma (NAMS) stake by 1,904% in Q2 2026, buying an estimated $565K and bringing the position to 18,038 shares worth $611K. The position accounts for ﹤0.01% of the portfolio, ranked #4478.

Wells Fargo first reported a position in NAMS in Q2 2023 and has held it in 13 quarters since. 194 funds tracked by Wall St. Rank hold NAMS as of Q2 2026.

Wells Fargo held 18,038 shares of NewAmsterdam Pharma worth $611K as of Q2 2026.
Wells Fargo bought 17,138 NewAmsterdam Pharma shares in Q2 2026, an estimated $565K.
NewAmsterdam Pharma made up ﹤0.01% of Wells Fargo's portfolio in Q2 2026, its #4478 holding.
Wells Fargo first reported a position in NewAmsterdam Pharma in Q2 2023 and has held it in 13 quarters since.
194 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q2 2026.

Based on Wells Fargo's 13F filing for Q2 2026, filed 14 Aug 2026.